glp 1 weight loss drugs Patients' Use GLP-1 for Loss, Benefit Gains Unlocking The Power of GLP-1

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Nature Medicine 2019;25:1096-1103

Approximately 66 million adults in Europe currently live with diabetes, representing a substantial patient population for GLP-1 therapies

GLP-1 receptor agonists work by mimicking the action of endogenous GLP-1, a hormone that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways

Canadian Medical Association Journal

The full therapeutic dose may not be reached until 16 to 20 weeks after initiation, which delays maximal efficacy but improves tolerability and treatment adherence